Literature DB >> 10831636

Steroid and cyclophosphamide in IgA nephropathy.

D Roccatello1, M Ferro, G Cesano, D Rossi, S Berutti, M Salomone, G Piccoli, L M Sena.   

Abstract

BACKGROUND: IgA nephropathy is associated with a wide spectrum of possible lesions. Therefore, different responses to anti-inflammatory or immunosuppressive therapies should be expected with acute inflammatory changes, which are predominantly reversible, and with prevalently sclerotic lesions.
METHODS: The effects of a combined schedule of prednisone and cyclophosphamide was analysed in the specific subset of IgA nephropathy patients with acute inflammatory histologic changes associated with haematuria and proteinuria. Two groups of patients, with similar histologic lesions and clinical presentation, were considered. The first group (12 patients) was treated within 1 week after renal biopsy; starting with three pulses of methylprednisolone (1 g) followed by oral prednisone (0.8 mg/kg body weight for 2 weeks, 0.6 mg/kg for another 2 weeks, 0.4 mg/kg for an additional 4 weeks, then slowly tapered by 5 mg each month until discontinuation) and 1.5 mg/kg cyclophosphamide for 2 months. A second sample of eight untreated patients served as a control group. Treated and untreated patients had diffuse mesangial proliferation with florid crescents (8-60% in treated and 10-40% in untreated patients) with mild degree of glomerular sclerosis and interstitial changes. Basal creatinine (167 micromol/l, range 79-371 vs 132 micromol/l, range 79-256) and proteinuria (3.0 g/24 h, 1.0-4.9 vs 3.3 g/24 h, 1.0-13.7) were not statistically different between treated and untreated patients respectively. Nine treated and six untreated patients were hypertensive. Blood pressure treatment did not include ACE-inhibitors.
RESULTS: Untreated patients' 5-year renal survival, as assessed by the Kaplan-Meier method, was found to be significantly lower than treated patients (37.5 vs 91.6%, log-rank P=0.01 and Breslow test P=0.008; relative risk to reach the endpoint of a 100% increase in serum creatinine=3.58, P=0.03).
CONCLUSION: This short course of therapy with prednisone and cyclophosphamide has been effective in a subset of IgA nephropathy patients with florid glomerular changes and major urinary abnormalities, turning off phlogistic activity and preventing subsequent progression toward renal failure.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10831636     DOI: 10.1093/ndt/15.6.833

Source DB:  PubMed          Journal:  Nephrol Dial Transplant        ISSN: 0931-0509            Impact factor:   5.992


  9 in total

Review 1.  Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?

Authors:  F M Rasche; F Keller; W G Rasche; S Schiekofer; A Boldt; U Sack; J Fahnert
Journal:  Clin Exp Immunol       Date:  2016-09-08       Impact factor: 4.330

2.  Sequential therapy with cyclophosphamide and mycophenolic acid in patients with progressive immunoglobulin A nephropathy: a long-term follow-up.

Authors:  F M Rasche; F Keller; W G Rasche; S Schiekofer; T Kahn; J Fahnert
Journal:  Clin Exp Immunol       Date:  2015-11-26       Impact factor: 4.330

3.  Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy.

Authors:  Claudio Pozzi; Simeone Andrulli; Antonello Pani; Patrizia Scaini; Lucia Del Vecchio; Giambattista Fogazzi; Bruno Vogt; Vincenzo De Cristofaro; Landino Allegri; Lino Cirami; Aldo Deni Procaccini; Francesco Locatelli
Journal:  J Am Soc Nephrol       Date:  2010-07-15       Impact factor: 10.121

4.  Effect of Cyclophosphamide and Glucocorticoid Therapy in IgA Nephropathy: A Single-Center Retrospective Analysis.

Authors:  Nicolas Beck; Gerd Walz; Johanna Schneider
Journal:  Kidney360       Date:  2022-01-19

Review 5.  [IgA nephropathy: frequent, but rarely diagnosed].

Authors:  J Floege; H-J Gröne
Journal:  Internist (Berl)       Date:  2003-09       Impact factor: 0.743

6.  In crescentic IgA nephropathy, fractional excretion of IgG in combination with nephron loss is the best predictor of progression and responsiveness to immunosuppression.

Authors:  Claudio Bazzi; Virginia Rizza; Sara Raimondi; Daniela Casellato; Pietro Napodano; Giuseppe D'Amico
Journal:  Clin J Am Soc Nephrol       Date:  2009-04-30       Impact factor: 8.237

7.  Long-term follow-up of patients with IgA nephropathy treated with prednisolone and cyclophosphamide therapy.

Authors:  Satoshi Oshima; Osamu Kawamura
Journal:  Clin Exp Nephrol       Date:  2008-03-08       Impact factor: 2.801

8.  Effect of corticosteroids combined with cyclophosphamide or mycophenolate mofetil therapy for IgA nephropathy with stage 3 or 4 chronic kidney disease: A retrospective cohort study.

Authors:  Qing Jia; Feng Ma; Jin Zhao; Xiaoxia Yang; Ruiling Sun; Rong Li; Shiren Sun
Journal:  Front Pharmacol       Date:  2022-08-31       Impact factor: 5.988

9.  A comparison of the effectiveness of cyclophosphamide, leflunomide, corticosteroids, or conservative management alone in patients with IgA nephropathy: a retrospective observational study.

Authors:  Shasha Chen; Qing Yin; Song Ren; Xiang Zhong; Wei Wang; Guisen Li; Li Wang
Journal:  Sci Rep       Date:  2018-09-12       Impact factor: 4.379

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.